2022 objectives successfully met, notably in the development of the two drug candidates: AEF0117: phase 2b study in the United States progressing as expected AEF0217: the compound's
Aelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Aelis Farma Has Participated in Two Symposiums Marking World Down Syndrome Day streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AEF0217 is being developed as the first treatment for cognitive deficits caused by a hyperactivity of the CB1 receptor, the first indication being those linked to Down syndrome (Trisomy 21), which